
Mettler-Toledo International MTD
$ 1 031.64
-0.99%
Quarterly report 2026-Q1
added 05-08-2026
Mettler-Toledo International Interest Expense 2011-2026 | MTD
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.5 M | 74.6 M | 77.4 M | 55.4 M | 43.2 M | 38.6 M | 37.4 M | 34.5 M | 32.8 M | 28 M | 27.5 M | 24.5 M | 22.7 M | 22.8 M | 23.2 M | 20.1 M | 25.1 M | 25.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 77.4 M | 20.1 M | 37.9 M |
Quarterly Interest Expense Mettler-Toledo International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 M | 17.7 M | 16.8 M | 16.7 M | - | 18.6 M | 19 M | 19.2 M | - | 20.3 M | 19.2 M | 18.2 M | - | 14.5 M | 12.8 M | 11.3 M | - | 11.8 M | 10.4 M | 9.47 M | - | 9.31 M | 9.58 M | 10.2 M | - | 9.8 M | 8.88 M | 9.09 M | - | 9 M | 8.31 M | 8.36 M | - | 8.25 M | 8.17 M | 7.74 M | - | 7.17 M | 6.87 M | 6.58 M | - | 7.03 M | 6.94 M | 6.72 M | - | 5.99 M | 5.96 M | 5.67 M | - | 5.56 M | 5.54 M | 5.4 M | - | 5.57 M | 5.71 M | 5.82 M | - | 5.89 M | 5.69 M | 5.71 M | 4.79 M | 4.71 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.3 M | 4.71 M | 9.98 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Co-Diagnostics
CODX
|
106 K | $ 1.29 | -21.17 % | $ 1.72 M | ||
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Fulgent Genetics
FLGT
|
561 K | $ 15.7 | -3.03 % | $ 475 M | ||
|
Agilent Technologies
A
|
81 M | $ 111.7 | -1.38 % | $ 34 B | ||
|
Castle Biosciences
CSTL
|
144 K | $ 19.13 | 1.32 % | $ 555 M | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
-292 M | $ 142.54 | -0.49 % | $ 22.7 B | ||
|
Interpace Biosciences
IDXG
|
-394 K | $ 1.76 | -2.22 % | $ 7.79 M | ||
|
CareDx, Inc
CDNA
|
524 K | $ 19.97 | -2.54 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
31.3 M | $ 93.91 | -2.86 % | $ 6.34 B | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Myriad Genetics
MYGN
|
800 K | $ 3.58 | -1.1 % | $ 332 M | ||
|
Medpace Holdings
MEDP
|
-5.34 M | $ 415.27 | -0.93 % | $ 12 B | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
NeoGenomics
NEO
|
296 K | $ 8.24 | -1.44 % | $ 1.06 B | ||
|
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
-95 K | $ 18.62 | -1.64 % | $ 417 M | ||
|
Charles River Laboratories International
CRL
|
-22.6 M | $ 150.85 | -5.2 % | $ 7.48 B | ||
|
Natera
NTRA
|
9.32 M | $ 186.36 | -5.36 % | $ 18.3 B | ||
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
288 M | $ 25.23 | -1.06 % | $ 23.9 B | ||
|
Senseonics Holdings
SENS
|
-23 K | $ 5.77 | -0.86 % | $ 241 M | ||
|
Guardant Health
GH
|
-10.5 M | $ 94.92 | -3.79 % | $ 11.9 B | ||
|
Personalis
PSNL
|
205 K | $ 6.36 | -5.22 % | $ 568 M | ||
|
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
337 M | $ 116.38 | -0.61 % | $ 9.6 B | ||
|
Soleno Therapeutics
SLNO
|
2.58 M | $ 53.01 | 0.04 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
367 | $ 2.34 | -2.9 % | $ 5.38 M | ||
|
Laboratory Corporation of America Holdings
LH
|
224 M | $ 250.4 | -1.43 % | $ 20.8 B | ||
|
Thermo Fisher Scientific
TMO
|
-12 M | $ 438.34 | -2.2 % | $ 165 B | ||
|
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.57 | -1.59 % | $ 205 M | ||
|
Celcuity
CELC
|
5.33 M | $ 137.68 | 2.2 % | $ 6.44 B | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
-903 K | $ 49.17 | -7.14 % | $ 2.94 B | ||
|
Waters Corporation
WAT
|
14.3 M | $ 329.22 | -1.2 % | $ 19.6 B | ||
|
Neogen Corporation
NEOG
|
38.1 M | $ 8.19 | -2.85 % | $ 1.78 B | ||
|
Quest Diagnostics Incorporated
DGX
|
26 M | $ 186.61 | -0.71 % | $ 20.7 B |